Unverified50% confidenceFactExact time

mRNA-4157/V940 is used in combination with Merck's immune checkpoint inhibitor Keytruda (pembrolizumab).

1

Sources

50%

Confidence

Long-term

Relevance

9/7/2026

First Seen

Sources

Moderna's Personalized Cancer Vaccine Succeeds in Phase 3 Trial, Stock Surges 110%

Related Entities

mRNA-4157/V940product Keytrudaproduct 帕博利珠单抗product

Related Claims

UnverifiedKeytruda is a PD-1 receptor-targeting monoclonal antibody that releases T cell anti-tumor activity by blocking the binding of PD-1 to PD-L1.56% similar

Cite This Claim

Stable URI

https://kongchang.com/claim/869771

API

curl https://kongchang.com/api/v1/knowledge/claims/869771

MCP

get_claim(id=869771)